Past European Partnerships

Historically starting with the 5th European Framework Programme (FP5) in 2000, the IPBS takes part to the global initiative against tuberculosis as one key partner of the “TB Vaccine Cluster”. The TBVAC Consortium brings in a large number of key partners from excellent laboratories from Europe, but also USA, Asia, Africa and Australia, many of which are global leaders in the field of tuberculosis. Under Horizon 2020, scientists and developers from 40 research partners have collaborated in the TBVAC2020 4-year project (2015-2019) coordinated by the Tuberculosis Vaccine Initiative (TBVI). []

IPBS took part in various European schemes, such as RESPIRE 2 and 3, and in two Initial Training Network (ITN): GLYCOGAN (2015-2019) Exploiting Glycosylation of Colorectal Cancer for the development of improved diagnostics and therapeutics and SBMP addressing the structural biology of membrane proteins (2008-2012).
[] []

Based on a solid and old collaboration with the University of Ljubljana, the IPBS developed an European Associated Laboratory (LEA) entitled “Pulsed Electric Fields Applications in Biology and Medicine”, abbreviated as “LEA EBAM”. This French-Slovenian “without walls” laboratory has been created in January 2011 for four years (2011-2014) and has been renewed for four additional years (2015-2018). []

IPBS teams are also members of European programs of cross-border cooperation, through the interregional (Spain-France-Andorra) POCTEFA 2014-2020 created to promote the sustainable development of the border territories of the three countries on both sides of the Pyrenees. []

Between 2010 and 2014, the research groups working on TB & Infection Biology at IPBS had participated to the SYSTEMTB consortium, together with 12 renowned institutes such as the Max Planck (Germany), the medical research council (UK) etc.

IPBS has also actively participated to the EU-Brazil project “TARKINAID” (2012-2015) aimed at the understanding and treating Chronic autoimmune and inflammatory diseases such as rheumatoid arthritis or chronic inflammatory lung diseases and in an ERA-NET funding on Antimicrobial resistance. [] []